Companies › Nippon Shinyaku
1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NS-089/NCNP-02 (Brogidirsen) Antisense oligonucleotide targeting DMD exon 45 skip | DMD | Phase 2 | Duchenne Muscular Dystrophy (DMD) | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05135663 | NS-089/NCNP-02 (Brogidirsen) | Phase 2 | Duchenne Muscular Dystrophy (DMD) | Neurology | Apr 2027 |
NS Pharma Dyne Therapeutics MED Institute NeuroPace Sarepta Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.